Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in patients wi...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ruijin Hospital
Collaborators
NCT06948110 · Autoimmune Diseases
NCT06342713 · Healthy Participants, Healthy Subjects, and more
NCT07275736 · Neurological Autoimmune Diseases
NCT07408336 · Autoimmune Diseases
NCT06575426 · Diabetes Mellitus, Type 1, Hypoglycemia, and more
Ruijin Hospital
Shanghai
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions